123 related articles for article (PubMed ID: 27890964)
21. The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.
Ma YY; Guan TP; Yao HB; Yu S; Chen LG; Xia YJ; He XJ; Wang HJ; Jiang XT; Tao HQ
PLoS One; 2013; 8(1):e55019. PubMed ID: 23383041
[TBL] [Abstract][Full Text] [Related]
22. Impact of MDM2 single nucleotide polymorphism on oral squamous cell carcinoma risk.
Xie JL; Yang JL; Liu DS; Xie YG; Ji P
Cell Biochem Biophys; 2015 Mar; 71(2):993-8. PubMed ID: 25323564
[TBL] [Abstract][Full Text] [Related]
23. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
24. Association of MDM2 gene SNP 309 polymorphism and human non-small cell lung cancer susceptibility: A meta-analysis.
Luan L; Wang H; Zhao B; Wang F; Shi J; Xu X
Pathol Res Pract; 2019 Sep; 215(9):152538. PubMed ID: 31326197
[TBL] [Abstract][Full Text] [Related]
25. Association of MDM2 promoter T309G polymorphism with oral cancer risk: A meta-analysis of 3,536 subjects.
Yang XI; Zhu Y; Ye D; Liu Y; Sun H; Ruan M; Liu W
Mol Clin Oncol; 2016 Jul; 5(1):175-180. PubMed ID: 27330794
[TBL] [Abstract][Full Text] [Related]
26.
Hua W; Zhang A; Duan P; Zhu J; Zhao Y; He J; Zhang Z
Onco Targets Ther; 2017; 10():3773-3780. PubMed ID: 28794641
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk.
Chen T; Yi SH; Liu XY; Liu ZG
Asian Pac J Cancer Prev; 2012; 13(9):4327-30. PubMed ID: 23167337
[TBL] [Abstract][Full Text] [Related]
28. MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis.
Chen QW; Chen H; Cheng JS; Meng ZQ
Tumour Biol; 2014 May; 35(5):4147-51. PubMed ID: 24379140
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.
Tang J; Shen L; Song S; An Z; Zhang C
Tumour Biol; 2014 Jan; 35(1):779-84. PubMed ID: 23979978
[TBL] [Abstract][Full Text] [Related]
30. Association between SNP309 and del1518 Polymorphism in MDM2 Homologue and Esophageal Squamous Cell Carcinoma Risk in Chinese Population of Shandong Province.
Zhang L; Zhu Z; Wu H; Wang K
Ann Clin Lab Sci; 2015; 45(4):433-7. PubMed ID: 26275695
[TBL] [Abstract][Full Text] [Related]
31. Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta-analysis.
Yin L; Shen G; Zhu B
Thorac Cancer; 2020 Mar; 11(3):672-678. PubMed ID: 31970867
[TBL] [Abstract][Full Text] [Related]
32. The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis.
Yang J; Gao W; Song NH; Wang W; Zhang JX; Lu P; Hua LX; Gu M
Asian J Androl; 2012 Sep; 14(5):726-31. PubMed ID: 22902907
[TBL] [Abstract][Full Text] [Related]
33. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Lind H; Zienolddiny S; Ekstrøm PO; Skaug V; Haugen A
Int J Cancer; 2006 Aug; 119(3):718-21. PubMed ID: 16496380
[TBL] [Abstract][Full Text] [Related]
34. MDM4 rs4245739 A > C polymorphism correlates with reduced overall cancer risk in a meta-analysis of 69477 subjects.
Xu C; Zhu J; Fu W; Liang Z; Song S; Zhao Y; Lyu L; Zhang A; He J; Duan P
Oncotarget; 2016 Nov; 7(44):71718-71726. PubMed ID: 27687591
[TBL] [Abstract][Full Text] [Related]
35. Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls.
Gao J; Kang AJ; Lin S; Dai ZJ; Zhang SQ; Liu D; Zhao Y; Yang PT; Wang M; Wang XJ
Ther Clin Risk Manag; 2014; 10():269-77. PubMed ID: 24790452
[TBL] [Abstract][Full Text] [Related]
36. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
[TBL] [Abstract][Full Text] [Related]
37. Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynecological cancer: A meta-analysis of case-control studies.
Zhang J; Zhang Y; Zhang Z
Medicine (Baltimore); 2018 Jan; 97(2):e9554. PubMed ID: 29480845
[TBL] [Abstract][Full Text] [Related]
38. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein A5 gene promoter region-1131T/C polymorphism is associated with risk of ischemic stroke and elevated triglyceride levels: a meta-analysis.
Pi Y; Zhang L; Yang Q; Li B; Guo L; Fang C; Gao C; Wang J; Xiang J; Li J
Cerebrovasc Dis; 2012; 33(6):558-65. PubMed ID: 22688093
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk.
Liu G; Wheatley-Price P; Zhou W; Park S; Heist RS; Asomaning K; Wain JC; Lynch TJ; Su L; Christiani DC
Int J Cancer; 2008 Feb; 122(4):915-8. PubMed ID: 17957785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
